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While influenza vaccines aim to decrease the incidence 
of severe influenza among high-risk groups, evidence 
of influenza vaccine effectiveness (IVE) among the 
influenza vaccine target population is sparse. We 
conducted a multicentre test-negative case–control 
study to estimate IVE against hospitalised laboratory-
confirmed influenza in the target population in 18 hos-
pitals in France, Italy, Lithuania and the Navarre and 
Valencia regions in Spain. All hospitalised patients 
aged ≥18 years, belonging to the target population 
presenting with influenza-like illness symptom onset 
within seven days were swabbed. Patients positive by 
reverse transcription polymerase chain reaction for 
influenza virus were cases and those negative were 
controls. Using logistic regression, we calculated IVE 
for each influenza virus subtype and adjusted it for 
month of symptom onset, study site, age and chronic 
conditions. Of the 1,972 patients included, 116 were 
positive for influenza A(H1N1)pdm09, 58 for A(H3N2) 
and 232 for influenza B. Adjusted IVE was 21.3% 
(95% confidence interval (CI): -25.2 to 50.6; n=1,628), 
61.8% (95% CI: 26.8 to 80.0; n=557) and 43.1% (95% 
CI: 21.2 to 58.9; n=1,526) against influenza A(H1N1)
pdm09, A(H3N2) and B respectively. Our results sug-
gest that the 2012/13 IVE was moderate against influ-
enza A(H3N2) and B and low against influenza A(H1N1)
pdm09. 
Background
Antigenic drifts of influenza viruses expose the popula-
tion to new but related influenza variants on a regular 
basis [1]. On the basis of a yearly revised composi-
tion of seasonal influenza vaccines, the World Health 
Organization (WHO) considers annual Influenza vac-
cination as the most efficient measure against influ-
enza [2]. Every year, the seasonal influenza vaccine 
licensure is obtained based on immunogenicity data 
[3]. While these immunogenicity data are thought to be 
valid for healthy adults [4], the development of corre-
lates of protection suited to vulnerable populations is 
still to be achieved [5].
The population targeted for influenza vaccination in 
Europe includes those at increased risk of exposure to 
influenza virus as well as of developing severe disease, 
especially disease resulting in hospitalisation or death 
[6]. Target groups for vaccination usually include adults 
over 59 or 64 years of age and people of any age with 
certain underlying medical conditions [7,8]. Measuring 
influenza vaccine effectiveness (IVE) in each influenza 
season is important for the following reasons: to iden-
tify vaccines types and brands with low IVE; to decide 
on alternative preventive strategies if early estimates 
of IVE are low (e.g. preventive use of antivirals among 
vulnerable individuals); and to help decide on the next 
season’s vaccine content. Repeated evidence of sub-
optimal IVE among the population targeted for annual 
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influenza vaccination would also further advocate the 
need for vaccines that are more effective in this popu-
lation. Moreover, there are ongoing scientific debates 
about the effect of repeated vaccination on the immu-
nological response induced by the seasonal influenza 
vaccine [9-11] and further evidence is needed.
In 2011, we launched a pilot study to estimate the 
IVE against laboratory-confirmed influenza hospitali-
sation using a network of hospitals in the European 
Union (EU) [12]. During the 2012/13 influenza season, 
co-circulation of influenza A(H1N1)pdm09, A(H3N2) 
and B/Victoria- and B/Yamagata-lineage viruses was 
reported in Europe [13]. The objective of the study pre-
sented here was to measure the 2012/13 seasonal IVE 
against hospitalisation with subtype-specific labora-
tory-confirmed influenza in a hospital network in four 
EU countries: France, Italy, Lithuania and Spain.
Methods
We conducted a case–control study using the test-neg-
ative design [14] in 18 hospitals located in five study 
sites: France (five hospitals), Italy (two), Lithuania 
(two), and the Navarre (four) and Valencia (five) regions 
in Spain. Each study site adapted a generic protocol 
[15] to the local context (Table 1).
Study population
The study population was all community-dwelling 
adults (18 years of age or older), belonging to the tar-
get groups for vaccination as defined locally [16-20], 
admitted to one of the participating hospitals with no 
contraindication for influenza vaccination. Patients 
were excluded if they had previously tested positive for 
influenza virus in the 2012/13 season or resided out-
side the hospital catchment area (for the 11 hospitals 
with known catchment area).
Study teams actively screened all patients admitted 
for potentially influenza-related conditions. These 
conditions included the following: acute myocardial 
infarction or acute coronary syndrome; heart failure; 
pneumonia and influenza; chronic pulmonary obstruc-
tive disease; myalgia; altered consciousness, convul-
sions, febrile-convulsions; respiratory abnormality; 
shortness of breath; respiratory or chest symptoms; 
acute cerebrovascular disease; sepsis; and systemic 
inflammatory response syndrome. Among them, study 
teams invited patients with an onset of influenza-like 
Table 1
Generic protocol adaptations in each study site, hospital-based influenza vaccine effectiveness study, four European 
countries, 2012/13
 Protocol adaptation France Italy Lithuania
Spain
Navarre Valencia
Additonal staff for the study Yes Yes No No Yes
Services Emergency ward Emergency wardinternal medicine unit
Emergency ward
Infectious disease 
hospital
All Emergency ward
Vaccine status ascertainment Patient Patient or GP Patient or GP Register Register and oral
Ascertainment of type of vaccine used Ecological data Individual data Ecological data Individual data Individual data
Exclusion based on place of residence No No No Yes Yes
Inclusion of patients unable to sign 
the consent form Yes Yes No Yes Yes
Type of respiratory specimen Nasal Nasal and pharyngeal One pharyngeal and two nasal
Nasal and 
pharyngeal
Nasal and 
pharyngeal
Data entry validation Coordination team Coordination team Coordination team
Coordination 
team
Double entry 
for laboratory 
results
Weekly quality 
checks
Study periodsa 
Influenza A(H1N1)pdm09
Week 1, 2013 Week 2, 2013 Week 52, 2012 Week 7, 2013 Week 47, 2012
Week 10, 2013 Week 8, 2013 Week 9, 2013 Week 11, 2013 Week 15, 2013
Influenza A(H3N2)
Week 52, 2012 Week 3, 2013 Week 3, 2013 Week 4, 2013 Week 9, 2013
Week 14, 2013 Week 6, 2013 Week 13, 2013 Week 13, 2013 Week 12, 2013
Influenza B
Week 50, 2012 Week 5, 2013 Week 4, 2013 Week 50, 2012 Week 51, 2012
Week 13, 2013 Week 9, 2013 Week 15, 2013 Week 11, 2013 Week 15, 2013
GP: general practitioner.
a The International Organization for Standardization’s week numbers were used, to ensure consistency across study sites.
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illness (ILI) symptoms (one systemic and one respira-
tory symptom) within the past seven days to partici-
pate. Those accepting to participate were swabbed and 
tested for influenza. Reverse transcription polymerase 
chain reaction (RT-PCR) was used to detect influenza 
viruses and to classify them as influenza A(H3N2), 
influenza A(H1N1)pdm2009 or influenza B. Patients 
positive for influenza were classified as cases of a 
given influenza type/subtype and those testing nega-
tive were controls.
We defined the study period as at least 15 days after 
the beginning of each site-specific seasonal influenza 
vaccination campaign until the end of the influenza 
season as declared by local influenza surveillance 
systems. For each of the influenza type/subtype analy-
ses, we excluded the controls with onset of symptoms 
before the week of the first laboratory-confirmed case 
or after the week of the last laboratory-confirmed 
case. We used the International Organization for 
Standardization’s week numbers [21] to ensure consist-
ency across study sites.
We considered patients as vaccinated against seasonal 
influenza if they had received at least one dose of the 
2012/13 influenza vaccine more than 14 days before 
onset of ILI symptoms. Patients not vaccinated or vac-
cinated less than 15 days before ILI onset were consid-
ered as unvaccinated.
Data collection
We collected data on the ILI episode, demographics, 
chronic diseases (Table 2), number of hospitalisations 
in the previous 12 months, number of consultations 
at the general practitioner (GP) in the previous three 
months, smoking status, vaccination against influenza 
in 2012/13 and 2011/12 and, for those aged 65 years 
and over, functional status before ILI onset using the 
Barthel score [22]. The data were gathered from hos-
pital medical records, face-to-face interviews with the 
patient and/or patient’s family and laboratory data-
bases. The vaccination status was obtained from vac-
cination registers in two study sites, interview with the 
patients and/or patient’s family in two sites and con-
tact with the patient’s physician in one site.
Table 2
Definition of the categories of chronic conditions according to the variables collected, hospital-based influenza vaccine 
effectiveness study, four European countries, 2012/13
Categories of chronic conditions Chronic conditions Study sites that collected the information
Cardiovascular disease
Cardiovascular diseasea FR, IT, LT, VA
Heart disease FR, IT, LT, NV, VA
Stroke FR, IT, LT, NV
Transient ischemic attack IT
Peripheral arterial disease IT, VA
Respiratory disease
Lung diseasesa FR, IT, LT, NV
Asthma IT, VA, LT
Chronic obstructive pulmonary disease IT, LT
Emphysema IT, LT
Mucoviscidosis FR, IT, LT
Bronchitis VA, LT
Metabolic and endocrine disorders
Diabetes FR, IT, NV, VA
Nutritional deficiency FR, IT, LT
Endocrine disease FR, IT, LT, VA
Haematological disease or cancer
Haematological cancer FR, IT, LT, NV
Anaemia/spleen condition FR, IT, LT, VA
Drepanocytosis FR, IT
Cancer FR, IT, LT, NV, VA
Immunodeficiency
Immunodeficiency FR, IT, LT, NV, VA
Rheumatological disease FR, IT, LT, NV
Hepatic disease FR, IT, LT, NV, VA
Renal disease FR, IT, LT, NV, VA
Obesityb FR, IT, LT, NV, VA
Neuromuscular disorder FR, IT
Dementia FR, IT, LT, NV, VA
FR: France; IT: Italy; LT: Lithuania; NV: Navarre, Spain; VA: Valencia, Spain.
a  May include the conditions from the same category listed below.
b  Defined as body mass index ≥30 kg/m2.
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Data analysis
Study sites transmitted anonymised datasets to the 
pooled analysis coordinator, through a password-
secured web-based platform. We ran a complete 
case analysis, excluding records for which laboratory 
results, vaccination status or potential confounding 
variables were missing.
To test for heterogeneity between study sites, we used 
Cochran’s Q-test and the I2 index [23]. The Q-test pro-
vides a p value that indicates the presence or not of 
heterogeneity. The I2 index quantifies the proportion of 
the variance attributable to differences between study 
sites. It is common to consider that I2 around 25%, 50% 
and 75% indicate low, medium and high heterogeneity, 
respectively.
We conducted separate analyses for each type/sub-
type of influenza. We estimated the pooled IVE as 1 
minus the odds ratio (OR) (expressed as a percentage) 
of being vaccinated in cases versus controls, using a 
one-stage method with study site as fixed effect in the 
model [24].
We assessed the presence of effect modification 
by comparing the time- and study site-adjusted OR 
(assuming that the test-negative design case–control 
study is a density case–control study implying adjust-
ment for the time of symptom onset) across strata of 
characteristics using the homogeneity test. We consid-
ered a variable as a confounder when the percentage 
change between the unadjusted and adjusted OR was 
greater than 15%.
We conducted a multivariable logistic regression anal-
ysis. In addition to study site and month of symptom 
onset, we adjusted the models for the covariates iden-
tified as potential confounders in the stratified analy-
sis as well as the presence of at least one underlying 
condition and the age that we modelled as a restricted 
cubic spline with four knots [25]. The likelihood ratio 
test was used to decide on the final models. We con-
ducted stratified analyses by age group (less than 65 
years, 65–79 years and 80 years and above).
To study the effect of previous influenza vaccination 
on laboratory-confirmed influenza, we conducted a 
stratified analysis using four vaccination status cate-
gories: vaccination in none of the seasons (2011/12 and 
2012/13), 2012/13 vaccination only, 2011/12 vaccination 
only and vaccination in both seasons and computed 
and compared IVE for each of these categories using 
vaccination in none of the seasons as a reference.
We carried out sensitivity analyses excluding the 
weeks when less than 10% of the patients included 
were positive for influenza, excluding patients who 
received antivirals between the onset of symptoms and 
swabbing and by restricting the analysis to patients 
swabbed within four days of symptoms onset. To avoid 
the inclusion of patients with acute manifestation of 
chronic respiratory illnesses rather than respiratory 
infection, we restricted our analysis to patients with no 
underlying respiratory conditions.
We ran all analyses with Stata v12 (Stata Corp LP, 
College Station, TX, United States).
Table 3
Number of records received by the pooled analysis coordinator and included in the pooled analysis by study site, hospital-
based influenza vaccine effectiveness study, four European countries, 2012/13
Type of record
Number of records per study site
Francea Italy Lithuaniab Navarre, Spain
Valencia,
Spain Total
Eligible records 433 84 184 93 1,535 2,329
Non-target groups for vaccination 78 14 96 18 102 308
Missing laboratory results 2 0 0 0 43 45
Unknown vaccination status 3 0 1 0 0 4
Total records used for the analyses 350 70 87 75 1,390 1,972
Influenza A(H1N1)pdm09 
Cases 20 10 20 9 57 116
Controls 213 39 24 24 1,213 1,513
Influenza A(H3N2) 
Cases 38 4 9 2 5 58
Controls 229 24 29 33 204 519
Influenza B 
Cases 62 13 25 17 115 232
Controls 219 31 28 45 971 1,294
a In France, one specimen of influenza A virus could not be subtyped. 
b In Lithuania, one patient was coinfected with A(H3N2) and A(H1N1)pdm09 viruses.
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Table 4
Characteristics of influenza A(H1N1)pdm09 (n=116), influenza A(H3N2) (n=58) and influenza B (n=232) cases and 
corresponding test-negative controls included in the study, hospital-based influenza vaccine effectiveness study, four 
European countriesa, 2012/13 (n=1,972)
 Charactertistic
A(H1N1)pdm09 A(H3N2) B
Controlsb
(n=1,513)
Cases
(n=116)
Controlsc
(n=519)
Cases
(n=58)
Controlsd
(n=1,294)
Cases
(n=232)
Number (%)e Number (%)e Number (%)e Number (%)e Number (%)e Number (%)e
Median age in years 77.0 63.0* 75.0 73.0 77.0 75.2
Age group in years
18–64 339 (22.4) 60 (51.7)* 146 (28.1) 14 (24.1) 301 (23.3) 60 (25.9)
65–79 563 (37.2) 42 (36.2)* 175 (33.7) 22 (37.9) 473 (36.6) 92 (39.7)
80–103 611 (40.4) 14 (12.1)* 198 (38.2) 22 (37.9) 520 (40.2) 80 (34.5)
Sex
Male 851 (56.2) 67 (57.8) 294 (56.6) 24 (41.4)* 718 (55.5) 108 (46.6)*
Vaccine status
2012/13 seasonal influenza vaccination 866 (57.2) 39 (33.6)* 296 (57.0) 20 (34.5)* 734 (56.7) 88 (37.9)*
2011/12 seasonal influenza vaccination 835 (55.3) 37 (31.9)* 296 (57.5) 25 (44.6) 702 (54.5) 102 (44.5)*
Presence of comorbidities
Metabolic and endocrine disorders 546 (36.1) 41 (35.3) 195 (37.6) 24 (41.4) 462 (35.7) 72 (31.0)
Cardiovascular disease 768 (50.8) 49 (42.2) 247 (47.6) 26 (44.8) 636 (49.1) 103 (44.6)
Renal disease 198 (13.1) 9 (7.8) 84 (16.2) 8 (13.8) 165 (12.8) 27 (11.7)
Respiratory disease 750 (49.6) 50 (43.5) 243 (46.8) 25 (43.1) 634 (49.0) 80 (34.6)*
Neuromuscular disorder 82 (5.6) 7 (8.0) 27 (5.9) 3 (6.4) 70 (5.7) 7 (3.7)
Hepatic disease 65 (4.3) 2 (1.7) 14 (2.7) 0 (0.0) 57 (4.4) 8 (3.5)
Immunodeficiency 102 (6.7) 8 (6.9) 40 (7.7) 5 (8.6) 87 (6.7) 16 (6.9)
Haematological disease or cancer 321 (21.7) 16 (14.5) 96 (19.2) 12 (21.8) 279 (21.6) 30 (13.0)*
Any chronic condition 
(of all chronic conditions collected in the 
study site)
1,404 (92.8) 106 (91.4) 473 (91.1) 52 (89.7) 1,195 (92.3) 192 (82.8)*
More than one chronic condition 1,013 (67.0) 62 (53.4)* 340 (65.5) 37 (63.8) 853 (65.9) 113 (48.7)*
Obesityf 423 (28.1) 26 (22.6) 127 (24.7) 10 (17.9) 359 (27.9) 54 (23.5)
Pregnancy 10 (0.7) 1 (1.3) 7 (2.0) 0 (0.0) 11 (1.0) 8 (4.7)*
Low functional statusg (among patients ≥65 
years) 232 (19.8) 9 (16.1) 5 (14.8) 4 (9.1) 187 (18.9) 34 (19.8)
Other potential confounders
More than one GP visit in previous 3 months 738 (49.1) 46 (39.7) 261 (51.3) 26 (46.4) 649 (50.7) 109 (48.0)
Hospitalisations in previous 12 months 582 (38.5) 32 (27.6)* 205 (39.6) 22 (37.9) 502 (38.8) 70 (30.2)*
Smoker status 
Current 277 (18.3) 39 (33.6)* 108 (20.8) 13 (22.4) 243 (18.8) 32 (13.9)*
Former 580 (38.3) 35 (30.2)* 173 (33.4) 16 (27.6) 485 (37.5) 58 (25.1)*
Never 656 (43.4) 42 (36.2)* 237 (45.8) 29 (50.0) 565 (43.7) 141 (61.0)*
Potential for misclassification
Swabbing delay <4 days 745 (49.2) 69 (59.5)* 233 (44.9) 24 (41.4) 621 (48.0) 90 (38.8)*
Antiviral treatment before swabbing 18 (1.2) 12 (10.4)* 17 (3.3) 5 (8.6) 18 (1.4) 17 (7.3)*
GP: general practitioner.
* p value for difference between cases and controls <0.05. 
a  France, Italy, Lithuania and Spain (Navarre and Valencia regions).
b  Comparisons were made with controls recruited between the week of the first case of influenza A(H1N1)pdm09 and the week of the last case 
of influenza A(H1N1)pdm09 (1,513 controls).
c  Comparisons were made with controls recruited between the week of the first case of influenza A(H3N2) and the week of the last case of 
influenza A(H3N2) (519 controls).
d  Comparisons were made with controls recruited between the week of the first case of influenza B and the week of the last case of influenza 
B (1,294 controls).
e  Unless otherwise indicated.
f  Defined as body mass index ≥30 kg/m2.
g  Determined using the Barthel score [22].
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Results
Overall, 2,329 eligible patients, of whom 2,021 
belonged to the target groups for influenza vaccina-
tion, were recruited in the 18 study hospitals (Table 
3). A total of 45 (2.2%) and four (0.2%) patients were 
excluded due to missing laboratory results and missing 
vaccination status, respectively. We included a total of 
1,972 patients in the analysis: 1,390 from Valencia (177 
cases), 350 from France (121 cases), 87 from Lithuania 
(53 cases), 75 from Navarre (28 cases) and 70 from Italy 
(27 cases).
Influenza A(H3N2), A(H1N1)pdm09 and B co-circu-
lated in all study sites (Table 1). The study site having 
included patients for the longest period of time was 
Valencia (week 47, 2012 to 15, 2013) and for the short-
est period was in Italy (week 2–8, 2013). The period of 
Table 5
Influenza vaccine effectiveness against influenza A(H1N1)pdm09, A(H3N2) and B, adjusted for various covariables by age 
group, hospital-based influenza vaccine effectiveness study, four European countriesa, 2012/13
Groups assessed A(H1N1)pdm09 A(H3N2) B
All target groups
Number of cases and controls 1,628 577 1,526
Number of cases; number of vaccinated cases 116; 39 58; 20 232; 88
Number of controls; number of vaccinated controls 1,512; 865 519; 296 1,294; 734
Variables used for adjustment of vaccine effectiveness Percentage influenza vaccine effectiveness (95% CI)
Study site 47.0 (18.8 to 65.4) 54.4 (16.1 to 75.2) 46.5 (27.7 to 60.4)
Study site and month of symptom onset 45.7 (16.4 to 64.8) 53.0 (13.2 to 74.5) 44.3 (24.3 to 59.0)
Study site, month of symptom onset and age 20.9 (−25.3 to 50.1) 61.9 (27.2 to 80.1) 46.9 (26.8 to 61.5)
Study site, month of symptom onset, age and presence of chronic 
conditions 21.3 (−25.2 to 50.6) 61.8 (26.8 to 80.0) 43.1 (21.2 to 58.9)
Patients aged 18–64 years belonging to target groups
Number of cases and controls 372b 143c 346d
Number of cases; number of vaccinated cases 60; 9 14; 3 60; 7
Number of controls; number of vaccinated controls 312; 105 129; 39 286; 91
Variables used for adjustment of vaccine effectiveness Percentage influenza vaccine effectiveness (95% CI)
Study site and month of onset 42.5 (−28.3 to 74.3) 26.1 (−215.9 to 82.7) 68.4 (25.7 to 86.6)
Study site, month of onset and presence of chronic conditions 41.8 (−30.7 to 74.1) NAc 66.0 (19.3 to 85.7)
Patients aged 65–79 years
Number of cases and controls 504e 181f 565
Number of cases; number of vaccinated cases 42; 18 22; 7 92; 40
Number of controls; number of vaccinated controls 462; 276 159; 91 473; 287
Variables used for adjustment of vaccine effectiveness Percentage influenza vaccine effectiveness (95% CI)
Study site and month of onset 44.2 (–9.0 to 71.4) 55.7 (–22.8 to 84.0) 37.3 (–2.1 to 61.5)
Study site, month of onset and presence of chronic conditions 43.8 (–10.7 to 71.5) 52.4 (–33.9 to 83.1) 28.2 (–18.9 to 56.6)
Patients aged 80–103 years
Number of cases and controls 623g 216h 600
Number of cases; number of vaccinated cases 14; 12 22; 10 80; 41
Number of controls; number of vaccinated controls 609; 412 194; 147 520; 348
Variables used for adjustment of vaccine effectiveness Percentage influenza vaccine effectiveness (95% CI)
Study site and month of symptom onset −171.7 (−1,170.7 to 41.9) 73.8 (30.0 to 90.2) 46.4 (9.6 to 68.2)
Study site, month of symptom onset and presence of chronic 
conditions NA
g 73.8 (29.9 to 90.2) 44.8 (6.7 to 67.4)
CI: confidence interval; NA: not applicable.
a  France, Italy, Lithuania and Spain (Navarre and Valencia regions).
b  A total of 27 controls dropped because no cases in November among patients less than 65 years.
c  A total of 17 controls dropped because no cases in December and April and in Italy among patients less than 65 years.  No adjustment for 
chronic disease because all A(H3N2) cases aged less than 65 years had chronic conditions.
d  A total of 15 controls dropped because no cases in April among patients less than 65 years.
e  A total of 101 controls dropped because no cases in December among patients aged 65–79 years.
f  A total of 16 controls dropped because no cases in December and in Navarre, Spain, among patients aged 65–79 years.
g  Two controls dropped because no cases in Lithuania among patients aged 80 years and over. No adjustment for chronic disease because all 
A(H1N1)pdm09 cases aged 80 years and over had chronic conditions.
h  Four controls dropped because no cases in April among patients aged 80 years and over. 
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recruitment was the longest for A(H1N1)pdm2009 (21 
weeks) and the shortest for A(H3N2) (15 weeks).
Of the 1,972 patients included in the pooled analy-
sis, 116 patients tested positive for influenza A(H1N1)
pdm09, 58 for A(H3N2) and 232 for influenza B. Two 
patients were coinfected with types A and B and one 
patient was coinfected with A(H3N2) and A(H1N1)
pdm09. One specimen of influenza A could not be 
subtyped.
Influenza A(H1N1)pdm09 cases were younger (63 vs 
77 years, p<0.05) than controls. A lower proportion of 
A(H1N1)pdm09 cases had more than one underlying 
condition (53.4% vs 67.0%, p<0.05), had been hospital-
ised in the previous year (27.6% vs 38.5%, p<0.05) and 
a higher proportion were current smokers (33.6% vs 
18.3%, p<0.05) compared with controls (Table 4).
Influenza A(H3N2) cases and controls were similar for 
all characteristics except for the proportion of male 
patients (41.4% vs 56.6%, p<0.05).
Compared with controls, a lower proportion of influ-
enza B cases had underlying conditions (82.8% vs 
92.3%, p<0.05), had been hospitalised in the previ-
ous year (30.2% vs 38.8%, p<0.05) and were smokers 
(13.9% vs 18.8% of current smokers, p<0.05).
The 2012/13 vaccine coverage was 57.2% among all 
controls (all influenza-negative patients included in 
the study), 33.6% among A(H1N1)pdm09, 34.5% among 
A(H3N2) and 37.9% among influenza B cases (Table 4).
The p values associated with the Q-test and the I2 index 
using models adjusted for age, month of symptom 
onset and chronic condition, testing for heterogeneity 
between study sites, were respectively 0.19 and 40.0% 
for A(H3N2), 0.10 and 48.3% for A(H1N1)pdm09 and 
0.08 and 56.2% for influenza B.
The overall adjusted A(H1N1)pdm09 IVE was 21.3% 
(95% confidence interval (CI): −25.2 to 50.6; n=1,628); 
41.8% (95% CI: −30.7 to 74.1; n=372) among the 18–64 
year-old patients and 43.8% (95% CI: −10.7 to 71.5; 
n=504) among those aged 65–79 years. Among patients 
aged 80 years and older, there were 14 A(H1N1)pdm09 
cases, including 12 vaccine failures (Table 5). Restricted 
to those aged less than 80 years-old, the adjusted IVE 
was 35.2% (95% CI: −9.1 to 61.5; n=1,004). Adjusted 
IVE against A(H1N1)pdm09 was 6.2% (95% CI: −110.4 to 
58.2; n=753) among patients vaccinated in the 2012/13 
season only, 26.6% (95% CI: −81.6 to 70.3; n=724) for 
those vaccinated in 2011/12 and 27.9% (95% CI: −20.5 
to 56.9; n=1,368) for those vaccinated in both seasons 
(Table 6).
Table 6
Crude and adjusted vaccine effectiveness against influenza A(H1N1)pdm09 (n=1,625), A(H3N2) (n=571) and B (n=1,518) by 
vaccination status, hospital-based influenza vaccine effectiveness study, four European countriesa, 2012/13
Influenza type Number of cases Number of controls Crude VEb (95% CI) Adjusted VEc (95% CI)
A(H1N1)pdm09 (n=1,625)
No vaccination in 2012/13 and 2011/12 71 539  –  –
2012/13 vaccination only 8 135 26.2 (−62.9 to 66.6) 6.2 (−110.4 to 58.2)
2011/12 vaccination only 6 108 39.8 (−47.1 to 75.4) 26.6 (−81.6 to 70.3)
2011/12 and 2012/13 vaccinations 31 727 52.8 (24.3 to 70.6) 27.9 (−20.5 to 56.9)
A(H3N2) (n=571)
No vaccination in 2012/13 and 2011/12 30 183  –  –
2012/13 vaccination only 1 36 65.3 (−176.6 to 95.7) 68.3 (−157.2 to 96.1)
2011/12 vaccination only 6 40 5.1 (−156.4 to 64.9) 12.3 (−140.7 to 68.1)
2011/12 and 2012/13 vaccinations 19 256 49.2 (1.7 to 73.8) 59.6 (18.5 to 80.0)
B (n=1,518)
No vaccination in 2012/13 and 2011/12 121 478 –  –
2012/13 vaccination only 6 109 69.5 (27.6 to 87.2) 68.3 (24.5 to 86.7)
2011/12 vaccination only 21 82 0.4 (−73.1 to 42.7) −5.6 (−84.5 to 39.6)
2011/12 and 2012/13 vaccinations 81 620 39.3 (15.5 to 56.3) 37.3 (10.7 to 56.0)
CI: confidence interval; VE: vaccine effectiveness.
a  France, Italy, Lithuania and Spain (Navarre and Valencia regions).
b  Adjustment for study site and month of symptom onset. 
c  Adjustment for study site, month of symptom onset, age and comorbidities. 
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The overall adjusted IVE against A(H3N2) was 61.8% 
(95% CI: 26.8 to 80.0; n=577) (Table 5). The adjusted IVE 
was 52.4% (95% CI: −33.9 to 83.1; n=181) among 65–79 
years patients and 73.8% (95% CI: 29.9 to 90.2; n=216) 
among those 80 years and older. Among patients aged 
less than 65 years, all cases had chronic conditions. 
In this age group, the IVE adjusted for month of symp-
tom onset and study site was 26.1% (95% CI: −215.9 to 
82.7; n=143). Adjusted IVE was 68.3% (95% CI: −157.2 
to 96.1; n=250) among patients vaccinated in 2012/13 
only and 59.6% (95% CI: 18.5 to 80.0; n=488) among 
patients vaccinated in 2011/12 and 2012/13 (Table 6).
The overall adjusted IVE against influenza B was 43.1% 
(95% CI: 21.2 to 58.9; n=1,526), 28.2% (95% CI: −18.9 
to 56.6; n=565) among patients aged 65–79 years and 
66.0% (95% CI: 19.3 to 85.7; n=346) among those 
younger than 65 years (Table 5). Adjusted IVE against 
influenza B was 68.3% (95% CI: 24.5 to 86.7; n=714) 
among patients vaccinated in 2012/13 only and 37.3% 
(95% CI: 10.7 to 56.0; n=1,300) in those vaccinated in 
both seasons (Table 6).
There were few changes in the IVE when conducting the 
sensitivity analyses (Table 7). The IVE against A(H1N1)
pdm09 was higher when restricted to patients with no 
chronic respiratory conditions (38.9% (95% CI: −20.3 
to 69.0) vs 21.3% (95% CI: −25.2 to 50.6)).
Discussion
Our results suggest that in the population targeted 
for the influenza vaccination, the 2012/13 IVE for lab-
oratory-confirmed hospitalised influenza was 21.3% 
against A(H1N1)pdm09, 61.8% against A(H3N2) and 
43.1% against B.
The adaptation of a generic protocol by 18 European 
hospitals enabled us to pool data and obtain a sample 
of 1,972 hospitalised ILI patients targeted for influenza 
vaccination. In a season with co-circulation of the three 
viruses, this large sample size allowed us to compute 
type-/subtype-specific estimates of IVE against hospi-
talised influenza and to further attempt to stratify by 
age group. However, stratified analyses led to esti-
mates with broad confidence intervals. Consequently, 
some results of the stratified analyses can only be 
used to generate hypotheses.
The test-negative design has been mainly discussed 
and validated for GP-based studies [26,27]. It is 
assumed that by restricting the study population to 
patients consulting for ILI, the health-seeking behav-
iour confounding effect (associated with propensity to 
get vaccinated and to go to the GP in case of influenza) 
is controlled for. Since in our study sites all people 
needing hospitalisation are likely to be hospitalised, 
we believe that confounding due to health-seeking 
behaviour is minimised.
In hospital-based studies, several outcomes could 
be used. If we were to measure IVE against influenza 
confirmed-severe acute respiratory infection (SARI), we 
would need to make sure that for both cases and con-
trols a respiratory infection was the cause of admis-
sion. We have chosen a broader case definition and a 
more sensitive inclusion criteria to cover a larger part of 
the influenza disease burden. As a consequence, some 
of the ILI in the seven days before admission may cor-
respond to an exacerbation of underlying respiratory 
conditions. This could lead to an overestimation of the 
Table 7
Adjusteda vaccine effectiveness against influenza A(H3N2), influenza A(H1N1)pdm09 and B viruses according to various 
restrictions, hospital-based influenza vaccine effectiveness study, four European countriesb, 2012/13
Restriction
 A(H1N1)pdm09 A(H3N2) B
Total number/
number of 
cases
Adjusted VE (95% CI)
Total number/
number of 
cases
Adjusted VE (95% 
CI)
Total number/
number of 
cases
Adjusted VE (95% 
CI)
No restriction 1,628/116 21.3 (−25.2 to 50.6) 577/58 61.8 (26.8 to 80.0) 1,526/232 43.1 (21.2 to 58.9)
No antiviral treatment 
started between symptom 
onset and swabbing
1,598/104 18.6 (−30.7 to 49.3) 555/53 59.4 (21.7 to 79.0) 1,491/215 40.5 (17.3 to 57.2)
Swabbing delay ≤4 days 1,147/88 14.9 (−47.1 to 50.8) 359/36 60.4 (10.0 to 82.5) 1,037/151 45.3 (18.8 to 63.2)
Weeks when ratio controls 
to cases was <9:1 1,019/109 29.8 (−15.1 to 57.2) 542/56 62.7 (27.5 to 80.8) 1,142/221 44.3 (21.6 to 60.4)
Patients with no chronic 
respiratory conditions 829/66 38.9 (−20.3 to 69.0) 304/33 57.8 (−4.3 to 82.9) 812/152 50.7 (24.1 to 68.0)
CI: confidence interval: VE: vaccine effectiveness.
a  Adjustment for study site, month of symptom onset, presence of any chronic condition and age.
b  France, Italy, Lithuania and Spain (Navarre and Valencia regions).
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IVE. Restricting our analysis to patients with no under-
lying respiratory conditions provides similar results 
and does not support this hypothesis. Furthermore, we 
adjusted for the presence and number of previous hos-
pitalisations for underlying conditions.
The inclusion of patients swabbed more than four days 
after symptoms onset or after antiviral treatment had 
started could have led to misclassification biases if 
viral clearance occurred before swabbing. However, 
analyses confined to patients swabbed within four 
days of symptom onset and to patients who did not 
receive antiviral treatment did not change the results.
Studies using the test-negative design may underes-
timate the IVE when the ratio of controls to cases is 
high, especially if the laboratory tests have low speci-
ficity [28]. In our study, all cases were confirmed by 
RT-PCR, which has high specificity [29]. In the analyses 
restricted to weeks when the control to case ratio was 
lower than 9:1 resulted in very similar IVE estimates.
The data quality was high with only 49/2,021 records 
with missing outcomes or exposures in the database. 
We believe that ascertainment of vaccination status 
through patient interviews in two of the five study 
sites has not introduced differential information bias 
as data were collected before laboratory testing.
Due to the small sample size in some study sites, the 
test of heterogeneity may have had no power to detect 
heterogeneity even if differences exist between study 
sites. Different IVE across study sites could be due to 
variations in circulating strains, different vaccines by 
study site or different measured and unmeasured con-
founding factors. Further typing of circulating strains 
would be valuable to discuss site-specific IVE with 
regard to the level of matching between vaccine and 
locally circulating strains. Different access to vaccina-
tion according to age and underlying condition and to 
hospitalisation [30] could partly explain variations in 
IVE across study sites. Finally, the presence of random 
errors cannot be ruled out due to low sample size by 
study site. A larger sample size would be needed to 
carry out a two-stage pooled analysis [24].
Our results suggest that, in people belonging to tar-
get groups for vaccination, the 2012/13 IVE varied by 
subtype and age group. However, we cannot exclude 
the possibility that the variability of IVE results by age 
group mainly reflects sample size limitations. Small 
stratum-specific sample sizes (and very small num-
ber of cases) lead to unstable results and do not allow 
for biological interpretation of age-specific results. 
Our results would suggest that IVE against A(H3N2) 
was higher among older age groups. This observation 
would be in contradiction to the principles of immune 
senescence. In addition to the sample-size limitations, 
and as discussed above, we cannot exclude a selection 
bias for our controls, which we adjusted for. However 
we used the same control group for the three subtypes 
and age-specific results vary by subtype. We consider 
that it is unlikely that confounding factors would differ 
by subtype.
When looking at the effect of repeated vaccination 
(over two consecutive seasons), similar patterns were 
observed for influenza A(H3N2) and B. The highest 
point estimate IVE was in patients vaccinated in 2012/13 
only, the lowest in those vaccinated in 2011/12 only and 
intermediate among those vaccinated both seasons. 
Such findings are consistent with recent reports from 
the Unites States and Australia [9,10,31]. The 2011/12 
vaccine included an A/Perth/16/2009(H3N2)-like virus 
and a B/Brisbane/60/2008-like virus, while the 2012/13 
vaccine included an A/Victoria/361/2011(H3N2)-like 
virus and a B/Wisconsin/1/2010-like (Yamagata lin-
eage). On the basis of European virological surveil-
lance data [13], the main circulating strains during the 
2012/13 season were an A/Victoria/361/2011(H3N2) 
(with some A/Texas/50/2012 circulation reported) and 
B/Wisconsin/1/2010-like (with some B/Estonia and B/
Massachusets/2/2012 circulation reported). These 
data support the absence of protection by the 2011/12 
seasonal vaccine on the 2012/13 circulating strains as 
they were not matched.
Some authors have discussed the hypothesis of atten-
uated immunological responses as a result of repeated 
vaccination. From a school-based study, Davies et al. 
[32] suggested that a natural infection in season 1 pro-
duces antibodies that have a larger potential to form 
high post-vaccination titres in season 2 than vaccine-
induced antibodies. Smith et al. [33] hypothesised 
that large antigenic distances between vaccines in 
seasons 1 and 2, and between vaccine in season 1 and 
epidemic strain in season 2, significantly increase the 
risk of infection among repeated vaccinees compared 
with those receiving the vaccine in season 2 only. 
Considering the antigenic differences between the 
2011/12 vaccine and the 2012/13 circulating strains, 
this hypothesis could explain our results, suggesting 
a higher IVE against influenza A(H3N2) and B among 
patients vaccinated in 2012/13 only compared with 
those vaccinated in 2011/12 and 2012/13. Further stud-
ies, including a longer history of vaccine uptake and 
natural infections would be of great value to better 
understand the effect of repeated vaccination on the 
immunological response to a new influenza seasonal 
vaccine and the level of clinical protection conferred to 
individuals.
Our results suggest a low IVE against A(H1N1)pdm09, 
especially among the elderly [34]. A total of 14 cases 
of influenza A(H1N1)pdm09 occurred among patients 
older than 80 years. While the majority of these cases 
(n=12) were vaccinated patients, small numbers make 
the IVE estimates hard to interpret in that age group. 
The IVE was similar for those vaccinated in 2011/12 
only or in both seasons. There was no effect for 
those vaccinated in 2012/13 only. The recommended 
A/California/7/2009(H1N1)pdm09-like virus strain 
10 www.eurosurveillance.org
was the same for the 2011/12 and 2012/13 vaccines 
and matched the 2012/13 circulating strains (some 
A/California/06/2009 also reported). Long-lasting 
immune response induced by trivalent inactivated vac-
cines was previously described [35] and some recent 
results suggest that frequent previous vaccinations 
may be effective for the current influenza season [11]. 
The absence of protection among patients vaccinated 
in 2012/13 only is difficult to understand and interpret; 
it may reflect the presence of associated (and unmeas-
ured) negative confounders for which repeated vacci-
nation may be a surrogate. In addition, other studies 
[36-38] suggest a decreasing effect in the season dif-
ficult to reconcile with a long-term effect between sea-
sons. Considering the small sample size in some of the 
vaccination groups in our study, we cannot exclude the 
possibility that this observation is due to chance.
Increasing the number of study sites in this network 
would allow a sufficient sample size to be reached 
early enough in the season to prompt the use of alter-
native prevention measures if a low IVE against hos-
pitalised cases is observed among the target group. 
Early estimates of IVE against hospitalised influenza 
are also a useful complement to guide the decision-
making of WHO experts regarding the composition of 
the next season’s vaccines. A larger sample size and 
good documentation of vaccine brands used would 
allow the computing of brand-specific IVE. To further 
study the effect of previous seasonal vaccination will 
require documenting past vaccination over several 
seasons. In addition, ways to measure past natural 
immunity may also be needed to better understand the 
complex immunity of influenza natural infection and 
vaccination.
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